Connect with us

Business

High Court rules Baroness Mone-linked company breached £122m Covid contract

Published

on

High Court rules Baroness Mone-linked company breached £122m Covid contract


Rachel ClunBusiness reporter

Getty Images Baroness Michelle Mone in the House of Lords wearing ceremonial robes. She has blonde hair.Getty Images

A company linked to peer Baroness Mone and her husband Doug Barrowman has been ordered to pay £122m in damages after a judge ruled it breached a government contract for the supply of personal protective equipment (PPE) during the Covid pandemic.

The Department of Health and Social Care sued PPE Medpro over claims the medical gowns it supplied did not comply with relevant healthcare standards.

The High Court ruled Medpro failed to prove whether or not its surgical gowns, which were to be used by NHS workers, had undergone a validated sterilisation process.

Chancellor Rachel Reeves said it was beyond her powers for Baroness Mone to be stripped of her peerage.

But speaking to Matt Chorley on BBC Radio 5 Live, Reeves said: “I hope she won’t be back in the House of Lords.”

Peerages can only be removed by an act of Parliament. While a life peerage cannot be relinquished, Baroness Mone could choose to resign from being a member of the House of Lords.

Reeves said she would “do everything” in her power “to get that money back” and that the money belongs “in our schools, in our hospitals and in our communities”.

During the outbreak of the Covid pandemic in 2020, the government scrambled to secure supplies of PPE as the country went into lockdown and hospitals across the country were reporting shortages of clothing and accessories to protect medics from the virus.

In May that year, PPE Medpro was set up by a consortium led by Baroness Mone’s husband, Doug Barrowman, and won its first government contract to supply masks through a so-called VIP lane after being recommended by Baroness Mone.

The judgement said the government later ordered 25 million sterile gowns from Medpro, which were delivered in August and October 2020, after being manufactured in China.

However, just before Christmas that year, the Department of Health served the company with a notice rejecting the gowns and asking for a refund.

The judgement said the government decided it was “not satisfied that the gowns were contractually compliant” after inspecting them, and claimed subsequent tests conducted found “a number of them were not sterile”.

Paul Stanley KC, representing the government, told the trial that of 140 gowns that were tested, 103 failed.

It led to the government launching legal action in 2022 through the High Court, claiming the gowns did not comply with the agreed contract.

Medpro, however, argued it had complied with the contract and that the gowns were sterile.

Having previously denied gaining directly from the contracts, Baroness Mone, a former Conservative peer and lingerie tycoon, admitted in December 2023 that she stood to benefit from tens of millions of pounds of profit.

She also admitted to the BBC that she and her husband lied about their involvement with Medpro to avoid “press intrusion”.

The court found firm’s director Anthony Page called on his “big gun” – Baroness Mone – during negotiations in order to secure the gown contract.

In the court ruling on Wednesday, Justice Cockerill said the contract between Medpro and the government was “complex”, but found that the company did in fact have to demonstrate it had undertaken a “validated sterilisation process”.

“That was not complied with by Medpro,” she said. “It followed that Medpro had breached the contract.”

The ruling also said the gowns lacked the “notified body number” required to mark them as sterilised, and that Medpro had provided no evidence such a process had taken place.

Medpro had also argued that the government could have sold the gowns if it no longer wanted them, or repurposed to be used as non-sterile or isolation gowns.

During the case, the company said any lack of sterility or valid sterility marking “did not prevent the said gowns from being used within the NHS or from being sold to third parties outside of the EU”.

Justice Cockerill said there were problems with that argument, including the fact that the NHS did not need any more isolation gowns.

However, she noted that the DHSC did not effectively reject the gowns within a reasonable timeframe, and also dismissed the government’s claim for £8.65m in storage costs over lack of evidence.

The judge ruled the company must pay £121,999,219 in damages, plus interest, however, it remains unclear how Medpro will pay the fee, with the company appointing administrators the day before the court decision.

Its last set of accounts said it only had £666,025 of shareholders’ funds.

The court said the firm had until 15 October to pay the damages to the government.

Speaking after the judgement, Chancellor Rachel Reeves said the government was working with administrators and “all different authorities” to try and claim the money.

Doug Barrowman and Michelle Mone pictured during an interview with the BBC

‘A win for the establishment’

In response to the ruling, Baroness Mone said it was “shocking but all too predictable”.

“It is nothing less than an Establishment win for the Government in a case that was too big for them to lose,” she said in a social media post.

A spokesperson for Mr Barrowman described the ruling as “a travesty of justice”.

“[Mrs Justice Cockerill’s] judgment bears little resemblance to what actually took place during the month-long trial, where PPE Medpro convincingly demonstrated that its gowns were sterile,” the spokesperson added.

Baroness Mone was once described as one of the UK’s most successful businesswomen, creating the gel-padded Ultimo bra in the late 1990s.

In 2015, then-Prime Minister David Cameron made her the government’s “entrepreneurship tsar”, and shortly after she became a Conservative peer.

The next year she announced she was in a relationship with Mr Barrowman, a billionaire businessman who founded The Knocks Group of Companies and was a director of Aston Management Limited.

In December 2022, Baroness Mone sought a leave of absence from the House of Lords.

Neither Baroness Mone nor Mr Barrowman appeared in court for the decision.

A separate National Crime Agency (NCA) investigation into Medpro was launched in May 2021, into suspected criminal offences committed over the procurement of PPE.

An NCA spokesperson said on Wednesday its investigation was ongoing.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

FTSE 100 hits another high despite concerns over US government shutdown

Published

on

FTSE 100 hits another high despite concerns over US government shutdown



The FTSE 100 hit another record high on Wednesday, despite concerns over the US shutdown, as pharmaceutical stocks powered higher, with AstraZeneca up 11% alone.

The FTSE 100 index closed up 96.00 points, 1.0%, at 9,446.43, beating its previous record close on Tuesday.

The blue chip index had earlier set a new best level of 9,457.91.

The FTSE 250 ended 34.14 points higher, 0.2%, at 22,049.70, and the AIM All-Share ended up 3.24 points, 0.4%, at 786.41.

AstraZeneca led the FTSE 100 and rose 11%, regaining its crown as the most valuable FTSE 100 stock from HSBC, while peers Hikma Pharmaceuticals and GSK rose 5.7% and 6.2% respectively.

On Tuesday, the Trump administration announced a deal granting Pfizer a three-year reprieve on planned tariffs as the New York-based, pharmaceutical company vowed to voluntarily lower the prices of unspecified drugs for US purchase.

Under the deal, Pfizer is to charge “most favoured nation” pricing – matching the lowest price offered in other wealthy nations – to Medicaid, the US health insurance program for low-income Americans.

The White House also said it would unveil a website – called TrumpRx – that would allow consumers to directly purchase some medications from manufacturers at discounted rates.

JPMorgan sees Pfizer’s agreement as a potential “bellwether for the sector” which, “we anticipate is likely to be replicated by EU pharma companies and should therefore result in a broadly manageable impact”, from most favourable nation drug pricing, “reassuring investors”.

In economic data, the downturn in UK manufacturing worsened in September as output, orders and employment all fell at sharper rates, survey results from S&P Global showed.

The seasonally adjusted manufacturing purchasing managers’ index dropped to 46.2 points in September from 47.0 in August, marking its lowest level since April and remaining below the neutral 50-point mark for the 12th straight month.

The final figure came in line with the flash estimate published last Tuesday.

Production contracted for the 11th consecutive month, with declines across consumer, intermediate, and investment goods. New orders fell for a 12th successive month, one of the steepest drops in two years, as firms cited subdued client confidence, uncertainty linked to US tariffs, and high energy and labour costs.

Elliott Jordan-Doak, senior UK economist at Pantheon Macroeconomics, said demand for UK manufacturing exports continues to be beset by tariff-related uncertainty, although he thinks the worst of the tariff-related shock has passed.

He only expects manufacturing output to rise slowly over the course of the second half of the year.

The pound was quoted higher at 1.3477 US dollars at the time of the London equity market close on Wednesday, compared to 1.3443 dollars on Tuesday. The euro stood at 1.1729 dollars, up slightly against 1.1727 dollars. Against the yen, the dollar was trading at 147.15 yen, lower compared to 147.98 yen.

The yield on the US 10-year Treasury was quoted at 4.13% stretched from 4.12% on Tuesday. The yield on the US 30-year Treasury stood at 4.72%, widened from 4.69%.

In European equities on Wednesday, the CAC 40 in Paris closed up 0.9%, while the DAX 40 in Frankfurt advanced 1.0%.

Stocks in New York were little changed at the time of the London close. The Dow Jones Industrial Average was up 0.1%, the S&P 500 index was flat and the Nasdaq Composite 0.1% lower.

The US government entered a shutdown at midnight, as Congress failed to strike a deal to keep programmes funded.

Joshua Mahony, analyst at Rostro, said with little sign of progress toward a deal, traders are preparing for the possibility that both jobless claims and Friday’s non-farm payrolls release will be delayed.

He noted that, historically, shutdowns have delivered bouts of volatility, but the precedent has been that weakness tends to be short-lived and presents “buying opportunities”.

“Markets may therefore face turbulence in the days ahead, although historical evidence points towards shutdown declines providing opportunities for bulls that can take advantage of short-term dislocation,” he commented.

Citi analyst Andrew Hollenhorst said the economic drag from the shutdown should be limited, but would become more significant if the shutdown lasts more than two weeks or if a larger number of federal workers are permanently laid off.

“An earlier resolution is possible, but we would not be surprised if this shutdown lasts several weeks,” he added.

With the US jobs report under threat of delay, figures from ADP took on added significance.

According to the payroll services provider, the US private sector shed 32,000 jobs in September, an outcome that fell short of the FXStreet cited expectation of 50,000 additions. In August, 3,000 jobs were lost, in a reading massively revised from an initially reported 54,000 rise in payrolls.

Morgan Stanley said the negative print keeps the Federal Reserve “on alert”, and predicted consecutive quarter point rate cuts through to the January Federal Open Market Committee meeting.

Back in London, JD Sports Fashion rose 6.8% following better-than-expected results from its retail partner, Nike.

Nike rose 5.4% in New York. Its products account for about 45% of JD’s sales and their fortunes are closely linked.

On the downside, Tesco was a weak feature, down 3.6%, ahead of half-year results on Thursday.

On the FTSE 250, Greggs climbed 6.4% after a reassuring trading statement.

The bakery chain said trading had picked up in August and September after the “unusually” hot July had hurt sales.

But analysts said the share price jump reflected the absence of a further profit downgrade, and a short squeeze, rather than a burst of renewed enthusiasm for the company.

Peel Hunt said: “The market will be relieved the update did not bring a downgrade, but the pressure is still to the downside of forecasts.

“Big issues such as the viability of evening trade, the long-term store ambition, and the value-for-money image are still open discussions. There is too much to prove, in our view.”

But Tate & Lyle plunged 12% after cutting sales and earnings guidance amid subdued trading.

Chief executive Nick Hampton said the group has seen a “slowdown in market demand, particularly in the last two months which, in turn, has slowed our recent performance.”

Tate & Lyle now expects full-year sales to be down by low-single digit percent compared to prior hopes for growth at, or slightly below, the bottom of the firm’s medium-term range of 4% to 6%.

Brent oil fell to 65.53 US dollars a barrel on Wednesday from 65.99 dollars late on Tuesday.

But gold remained in demand, trading at 3,862.37 dollars an ounce on Wednesday, up against 3,836.50 dollars on Tuesday.

The biggest risers on the FTSE 100 were: AstraZeneca, up 1,254 pence at 12,436p; JD Sports Fashion, up 6.5p at 101.8p; GSK, up 97p at 1,671.5p; Hikma Pharmaceuticals, up 97p at 1,795p; and Melrose Industries, up 22p at 630p.

The biggest fallers on the FTSE 100 were: Babcock International, down 50p at 1,280p; Tesco, down 15.8p at 429.7p; Coca-Cola HBC, down 110p at 3,394p; Games Workshop, down 330p at 14,200p; and Imperial Brands, down 67p at 3,091p.

Thursday’s global economic calendar has eurozone unemployment data, and US weekly jobless claims figures and factory orders figures.

Thursday’s UK corporate calendar has half-year results from the UK’s largest retailer, Tesco.

Contributed by Alliance News



Source link

Continue Reading

Business

Toy maker Jellycat plans to pay owners £110m after profits double

Published

on

Toy maker Jellycat plans to pay owners £110m after profits double


Toy maker Jellycat is planning to pay its owners £110m in dividends after it more than doubled its annual profit in 2024.

From eggs with sad faces to smiling peanuts, the Jellycat craze has made a big impact on the toy industry.

Its viral cuddly toys are sold all over the world and made the company a before-tax profit of £139m in 2024, up from £67m the previous year.

Chief executive, Arnaud Meysselle, said Jellycat was “humbled” by its growth and will continue to “bring more characters to life”.

Jellycat founder and chairman Thomas Gatacre said: “Our mission is simple: to create joy and try to be the most loved soft toy company in the world.”

First reported by the Financial Times, Jellycat’s most recent Companies House accounts show the firm saw a 66% increase in revenue to £333m for the year to 31 December.

The dividends the privately owned company plans to pay are a 75% increase from the £63m paid out to its owners the previous year.

Mr Gatacre said the Jellycat team has been running “faster than ever” to keep up with demand for the soft toys in 80 countries.

He added that the company is striving to make sure “every Jellycat arrives in tip top condition, build to last, and made responsibly”.

Jellycat’s success has been linked to its popularity on social media and a rise in adults buying toys for themselves.

As well as just selling the toys, Jellycat has a range of pop-up “experiences”.

Currently at London’s Selfridges, you can buy fish and chips soft toys, sold to you by an assistant pretending to fry and put salt and vinegar on your selected teddies.

In New York, you can visit a Jellycat diner and Paris has its own Jellycat patisserie with adults lining up to buy the toys.

Videos of such experiences have millions of views online, with fans essentially advertising to each other.



Source link

Continue Reading

Business

EVs, big SUVs drive Ford Q3 U.S. sales up 8.2%

Published

on

EVs, big SUVs drive Ford Q3 U.S. sales up 8.2%


Ford Mustang Mach-E and F-150 Lightning on display at the New York International Auto Show on March 28, 2024.

Danielle DeVries | CNBC

DETROIT – Sales of electric vehicles and large SUVs drove Ford Motor‘s third-quarter sales up by 8.2%, the Detroit automaker reported Wednesday.

Ford said sales of all-electric vehicles increased by 30.2% during the period to a new quarterly record of more than 30,600 units. Its “electrified” vehicles, including EVs and hybrids, increased 20% compared with the same period a year earlier.

Sales of Ford’s SUVs increased nearly 10% during the quarter, including massive gains for its larger SUVs as well as the Mustang Mach E EV, which was up 51% from a year earlier.

EV sales during the third quarter are expected to be a record, as buyers pulled ahead plans to purchase a new zero-emissions vehicle ahead federal EV incentives of up to $7,500 ending in September.

Ford CEO Jim Farley on Tuesday said he “wouldn’t be surprised” if sales of EVs fell from an industry market share of around 10% to 12% this month — which is expected to be a record — to 5% after the incentive program ends.

Cox Automotive forecasts sales of EVs hit 410,000 during the third quarter, up 21% from a year earlier. That would easily be the highest amount of EVs ever sold in a quarter in the U.S., as well as a record 10% market share.

Sales of EVs as well as plug-in hybrid electric vehicles that also qualified for federal incentives are expected to assist in boosting third quarter vehicle sales up between 4% and 7%, according to forecasts from Cox and CarMax’s Edmunds.

This is breaking news. Please check back for additional details.



Source link

Continue Reading

Trending